1	Title: COVID-19 vaccine effectiveness against progression to in-hospital mortality — Zambia, 2021-2022
2	
3	Authors: Duncan Chanda ^{1,2} * [†] ; Jonas Z Hines ³ *; Megumi Itoh ³ ; Sombo Fwoloshi ^{1,2,4} ; Peter A Minchella ³ ;
4	Khozya D. Zyambo ^{1,2} ; Suilanji Sivile ^{1,2} ; Davies Kampamba ² ; Bob Chirwa ² ; Raphael Chanda ¹ ; Katongo
5	Mutengo ⁵ ; Mazinga F. Kayembe ⁶ ; Webster Chewe ¹ ; Peter Chipimo ⁷ ; Aggrey Mweemba ⁸ ; Simon Agolory ³ ;
6	Lloyd B. Mulenga ^{1,2}
7	
8	Affiliations:
9	¹ University Teaching Hospital, Lusaka, Zambia
10	² Ministry of Health, Lusaka, Zambia
11	³ U.S. Centers for Disease Control and Prevention, Lusaka, Zambia
12	⁴ University of Zambia School of Medicine, Lusaka, Zambia
13	⁵ Livingstone Teaching Hospital, Livingstone, Zambia
14	⁶ Kitwe Teaching Hospital, Kitwe, Zambia
15	⁷ Zambia National Public Health Institute, Lusaka, Zambia
16	⁸ Levy Mwanawasa University Teaching Hospital, Lusaka, Zambia
17	
18	*These authors contributed equally to this report
19	[†] Corresponding author:
20	Duncan Chanda
21	University Teaching Hospital
22	Lusaka, Zambia
23	duncanchanda@gmail.com
24	

25	Keywords: SARS-CoV-2; COVID-19/mortality; COVID-19 Vaccines; SARS-CoV-2; Vaccine efficacy; Zambia;
26	Africa
27	
28	Word count
29	- Abstract: 250
30	- Article: 2,474
31	
32	Key points
33	- Receipt of ≥1 COVID-19 vaccine dose reduced progression to in-hospital mortality in Zambia by
34	64.8%
35	- Mortality benefit of COVID-19 vaccines was sustained during the period of omicron transmission
36	in Zambia
37	

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Abstract Background: COVID-19 vaccines are highly effective for reducing severe disease and mortality. However, vaccine effectiveness data is limited from sub-Saharan Africa, where SARS-CoV-2 epidemiology has differed from other regions. We report COVID-19 vaccine effectiveness against progression to inhospital mortality in Zambia. Methods: We conducted a retrospective cohort study among admitted patients at eight COVID-19 treatment centers across Zambia during April 2021 through March 2022. Patient demographic and clinical information including vaccination status and hospitalization outcome (discharged or died) were collected. Multivariable logistic regression was used to assess the odds of in-hospital mortality by vaccination status, adjusted for age, sex, number of comorbid conditions, disease severity, and COVID-19 treatment center. Vaccine effectiveness of ≥1 vaccine dose was calculated from the adjusted odds ratio. Results: Among 1,653 patients with data on their vaccination status and hospitalization outcome, 365 (22.1%) died. Overall, 236 (14.3%) patients had received ≥1 vaccine dose before hospital admission. For patients who had received ≥1 vaccine dose, 22 (9.3%) died compared with 343 (24.2%) among unvaccinated patients (p <0.01). The median time since receipt of a first vaccine dose was 52.5 days (IQR: 28-107). Vaccine effectiveness for progression to in-hospital mortality among hospitalized patients was 64.8% (95% CI: 42.3-79.4%). Conclusions: Among patients admitted to COVID-19 treatment centers in Zambia, COVID-19 vaccination was associated with lower progression to in-hospital mortality. These data are consistent with evidence

- from other countries demonstrating benefit of COVID-19 vaccination against severe complications.
- Vaccination is a critical tool for reducing the consequences of COVID-19 in Zambia.

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Introduction Since the onset of the COVID-19 pandemic, >170,000 persons have died of COVID-19 in sub-Saharan Africa (1). In Zambia, from March 20, 2020 to July 13, 2022, a total of 327,570 confirmed cases and 4,009 confirmed deaths were recorded (2), although the true number of infections and deaths was likely greater (3,4). As of February 2022, African countries had received more than 587 million vaccine doses, enough to vaccinate ~360 million people (which is ~37% doses needed to reach vaccination targets) (1). However, through April 2022, only 14% of the eligible population in sub-Saharan Africa had been fully vaccinated (1). The ChAdOx1-S COVID-19 vaccine became available in Zambia in April 2021 and approximately one year later, ~2.3 million persons in Zambia were fully vaccinated (22% of persons aged ≥12 years, the eligible population) (2). In addition to poor access to COVID-19 vaccines for much of 2021, several other challenges hindered vaccination programs in Zambia, including sub-optimal access to preventive health care/routine immunization, under-resourced health care systems, inadequate cold chain systems, lack of awareness of benefits of vaccination, and vaccine misconceptions and misinformation. COVID-19 vaccines have demonstrated excellent efficacy in clinical trials and good effectiveness in realworld observational studies, including against variants of concern and in people who have had prior COVID-19 infections (5-7). In particular, COVID-19 vaccines substantially reduce risk of severe disease and mortality (8,9). Yet, there is paucity of vaccine efficacy and effectiveness data from countries in sub-Saharan Africa. Most of the vaccine evidence from Africa have originated from South Africa, where several vaccine clinical trials have been conducted and observational vaccine effectiveness (VE) studies have been published (5,10-13). A single dose of the Ad26.COV2.S vaccine was associated with lower hospitalizations and mortality during beta and delta waves in South Africa (11), and additional evidence

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

demonstrated effectiveness against COVID-19 hospitalizations during the omicron wave (5). In Zambia, full receipt of a primary COVID-19 vaccine was associated with lower SARS-CoV-2 infections and symptomatic illness during an outbreak in a prison when omicron was the dominant variant (13). However, data from other countries in sub-Saharan Africa is limited to date. Filling the COVID-19 vaccine evidence gap in Africa is important to counter misinformation and skepticism toward research from other parts of the world (14,15). Furthermore, SARS-CoV-2 epidemiology in Africa has differed from elsewhere, with fewer confirmed cases and deaths, lower symptomatic rates, yet high evidence of infection-induced immunity (16-18). Furthermore, many countries in sub-Saharan Africa have a high burden of persons living with HIV (PLHIV) and tuberculosis, which are conditions associated with increased risk of poor outcomes from COVID-19 (19,20). Lastly, differences in social and health system structures might impact vaccine delivery. Therefore, more realworld data on COVID-19 vaccines from countries in Africa are needed. We assessed COVID-19 VE against progression to in-hospital mortality in patients hospitalized with COVID-19 in Zambia. Methodology We conducted a retrospective cohort study of patients admitted to COVID-19 treatment centers in Zambia to assess COVID-19 VE against progression to in-hospital mortality between April 15, 2021 (when Zambia first began offering COVID-19 vaccines) and March 31, 2022. Since the pandemic onset, patients diagnosed with COVID-19 requiring in-patient admission in Zambia were admitted to COVID-19 treatment centers that had specifically designated isolation and treatment units staffed by clinicians and nurses trained in COVID-19 clinical management (21). The COVID-19 clinical outcomes study was conceived during the early weeks of the COVID-19 epidemic in Zambia and eventually included eight COVID-19 treatment centers in five cities: Lusaka (four treatment centers), Ndola, Kitwe, Kabwe, and

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

Livingstone (22). Data on relative variant genome frequency by region from GISAID (Global Initiative on Sharing Avian Influenza Data) were utilized to define the SARS-CoV-2 variant that was circulating during each wave (23). ChAdOx1-S COVID-19 vaccine was the first vaccine type available in Zambia and by late 2021, Ad26.COV2.S, mRNA-127, BNT162b2, and Sinopharm BBIBP-CorV were available in the country. An additional vaccine dose after completing a primary vaccine series (i.e., "booster") became available in Zambia in January 2022. The study protocol was approved by the University of Zambia Biomedical Research Ethics Committee; it was also reviewed in accordance with the US Centers for Disease Control and Prevention (CDC) human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes. Patients who provided verbal consent for clinical care at participating treatment centers had demographic and clinical data collected at admission and during hospitalization until they were discharged or died. Data were retrospectively abstracted from clinical records using a standardized case record form adapted from WHO (24) and entered into REDCap (Research Electronic Data Capture) electronic data capture tools by trained staff at a later date (25). Vaccination information was collected from patients during clinical care and recorded in their charts. Proof of vaccination included self-report and/or review of vaccine card. For those with missing vaccine information, attempts were made to cross-reference the electronic national vaccine registry to improve data completeness. Severe COVID-19 was defined as having an oxygen saturation (SpO2) <90%, respiratory rate >30 breaths/minute, or need for oxygen therapy (26). The number of self-reported comorbidities was summed for each patient, including cardiac disease, hypertension, diabetes, other pulmonary disease, HIV, tuberculosis (active or previous), asthma, kidney disease, liver disease, neurological disorders, asplenia, malignant neoplasms,

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

and current smoking. History of prior COVID-19 was not available for patients, although the reliability of this history is not clear given a low case detection proportion in Zambia (3). Full vaccination was defined as receiving the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days prior to COVID-19 treatment center admission. Partial vaccination was defined as receiving the 1st dose of a two-dose vaccine ≥14 days prior to admission but either not yet receiving the 2nd dose or receiving the 2nd dose ≤13 days prior to admission. Those vaccinated with their 1st COVID-19 vaccine dose ≤13 days prior to admission were considered indeterminate and those with missing vaccine dates were classified as such. Because vaccination dates were missing for many patients with known vaccination status, we also created a separate category of patients who received ≥1 COVID-19 vaccine dose and used this as our primary predictor variable (with full/partial vaccination status being secondary analyses). The main outcome variable was categorized as discharged from hospital or died in the hospital. Length of stay was calculated as the days between admission and discharge or death. Patients whose vaccination status or hospitalization outcomes could not be determined were excluded from the analyses. The analysis was restricted to patients admitted during the period that COVID-19 vaccines were available in Zambia (April 15, 2021, through March 31, 2022). We used chi-square test and student's ttest to compare categorical and continuous variables, respectively. We used multivariable logistic regression to calculate the odds of in-hospital mortality by vaccination status, adjusting for age, sex, number of comorbid conditions, disease severity at admission, hospitalization month, and COVID-19 treatment center. VE was calculated as 1 minus the adjusted odds ratio times 100. We did secondary analyses to calculate VE by full/partial vaccination status, vaccine type, the predominant circulating variant (i.e., delta from April to November 2021, and omicron [subvariants B1 and B2 (23)] from

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

December 2021 through March 2022 (27)), and HIV status. Additionally, we analyzed if there was an association between progression to in-hospital mortality and predominant variant periods (delta versus omicron waves), adjusting for patients' vaccination status. Results Overall, 2,385 persons had data on their hospitalization course abstracted at a COVID-19 treatment center in Zambia during April 2021 through March 2022. Of patients with data abstracted, 1,821 (76.4%) had vaccination status documented (815 [61.5%] persons during the delta variant predominant period and 1,006 [94.9%] persons during the omicron variant predominant period). Among patients with known vaccination status, 1,653 (69.3% of total) had a known hospitalization outcome (Figure 1). The median age of participants was 47 years (interquartile range [IQR]: 30-65 years) and females accounted for 852 (51.5%) patients (Table 1). Overall, 1,065 (64.4%) patients reported having at least one comorbidity, with 266 (17.9%) patients reporting having HIV infection (compared to national prevalence of 11.1% in persons aged 15-49 years (28)). The average length of stay was 2.5 days and 365 (22.1%) patients died during their hospitalization. Two-hundred thirty-six (14.3%) patients had received ≥1 vaccine dose before hospital admission, of whom 55 (23.3%) were fully vaccinated, 30 (12.7%) were partially vaccinated, 8 (3.4%) had an indeterminate vaccination status, and 143 (60.6%) were missing information on vaccination date(s) (Table 1). No patient had a record of receiving a 3rd vaccine dose. The median time since receipt of a first vaccine dose was 52.5 days (IQR: 28-107).

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

The average length of stay for patients with ≥1 vaccine dose was 1.9 days versus 2.6 days for unvaccinated patients (p <0.01,) (Table 1). Twenty-two (9.3%) patients reporting ≥1 vaccine dose died compared to 343 (24.2%) unvaccinated patients (p <0.01). VE of ≥1 COVID-19 vaccine dose against progression to in-hospital mortality was 64.8% (95% confidence interval [CI]: 42.3-79.4) (Table 2). VE of ≥1 vaccine dose during the period when delta was dominant was 65.0% (95% CI: 22.5-85.8) and during the period when omicron was dominant was 64.8% (95% CI: 31.4-82.9). Among the 266 patients with HIV, 5 (14.3%) who had received ≥1 COVID-19 vaccine dose died compared to 61 (26.4%) who were unvaccinated (p = 0.18). VE of ≥1 COVID-19 vaccine dose against progression to in-hospital mortality among PLHIV was 53.6% (-15.6-84.7). In-hospital mortality among patients in the study was higher during the delta variant predominant period than the omicron variant predominant period (31.1% vs. 14.5%; p<0.01; odds ratio: 2.7 [95% CI: 2.1-3.4]) (Table 3). Adjusting for the different vaccination coverage of patients between waves (6.1% during delta versus 21.1% during omicron) did not appreciably change the odds of in-hospital mortality (adjusted odds ratio: 2.4 [95% CI: 1.9-3.1]). Discussion Patients vaccinated against COVID-19 had lower progression to in-hospital mortality in Zambia, a finding that was consistent during periods when delta and omicron were the dominant variants circulating in the country. These data from Zambia expand on limited evidence of COVID-19 VE in Africa (5,10-13). COVID-19 vaccination uptake in Africa has lagged other regions but evidence suggests that they are a critical tool for reducing morbidity and mortality from COVID-19. Sharing local evidence of the benefit of COVID-19 vaccine in Zambia might increase vaccine uptake.

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

Omicron variant of SARS-CoV-2 has mutations that enable it to evade prior immunity, resulting in decreased VE (6). However, protection from severe COVID-19 outcomes is the most conserved vaccine effect across different variants, especially following a booster dose (9,29,30). In our study, there was no decrement in VE against progression to in-hospital mortality when omicron was the predominant variant in Zambia (compared to when delta was predominant). Patients in this analysis had been vaccinated relatively recent (i.e., less than two months), which could explain preserved VE (6); additionally, data from before the omicron surge in the U.S. indicate preserved VE against hospitalization of a single dose adenovirus vaccine for at least six months (31,32). Even though VE remained similar between the delta and omicron waves in this study, the in-hospital mortality risk was lower during the omicron wave. However, this mortality difference was not driven by higher vaccination coverage among patients during the omicron wave. This finding is similar to those in a study by Modes et al. demonstrating that in one U.S. hospital, fewer fully vaccinated patients died inhospital during the omicron wave compared to the delta wave (33). This suggests other factors like patient characteristics (e.g., greater proportion of patients with infection-induced immunity during the omicron wave, higher risk patients admitted during the delta wave), system/environmental factors (e.g., relative availability of hospital beds or oxygen supply in Zambia, which were much more constrained during the delta wave than during the omicron wave), and/or virus characteristics (e.g., omicron lower replication competence in lung parenchyma (34)) could be responsible for the mortality difference by wave in Zambia (20). Some clinical trials for COVID-19 vaccines included PLHIV, although the numbers were too small to derive definitive evidence of efficacy in PLHIV (12,35). Based on immunological studies, vaccines are

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

expected to work well in this high-risk population (36). The Ad26.COV2.S vaccine has been demonstrated to reduce hospitalizations and deaths among PLHIV in South Africa (11), and in Russia, the Gam-COVID-VAC vaccines was shown to be effective in PLHIV, especially for severe disease (37). Although COVID-19 vaccination among PLHIV appeared to be effective against progression to in-hospital mortality in this study, the effect was not statistically significant. The inclusion of additional PLHIV in this study could provide a clearer evidence on this important topic in Zambia, where there is a high burden of HIV (28). Vaccinated patients in this study were also less likely than unvaccinated patients to be admitted to treatment centers with severe COVID-19, suggesting that vaccination also helped prevent this outcome. Although vaccine coverage in this study was low, it varied by geographic location, suggesting opportunities to learn from best practices in some areas to help other areas increase vaccine coverage. Our study had several limitations. Data were not available describing either national COVID-19-related hospitalization numbers or COVID-19 hospitalization rates by facility, limiting our understanding of the study's generalizability. As with many studies conducted during emergency responses, data completeness for some key variables was a challenge that impacted our sample size and resulted in wide confidence intervals. Additionally, the lack of vaccination dose numbers and dates for many participants necessitate use of a non-standard category (i.e., ≥1 vaccine dose) for the primary analysis to avoid excessive loss of participants; the similarity of VE estimates for full and missing vaccination statuses could indicate that many patients with missing vaccination status were in fact fully vaccinated. Additionally, given high levels of infection-induced immunity in Africa (16), hybrid immunity likely confers substantial protection against severe consequence of COVID-19 in Zambia (38). Variant periods were defined based on predominant variants in GISAID data in Zambia and not on sequencing results

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

from patients in the study. HIV status was self-reported, which could have led to biased VE findings in PLHIV. Lastly, there are potentially other unaccounted for confounders which couldn't be factored into the VE analysis. Vaccination is a critical tool to reduce the consequences of the SARS-CoV-2 epidemic. These findings are among the first from countries in Africa, and such real-world evidence of COVID-19 vaccines could help increase vaccination in a region that lags the rest of the world by providing local evidence of vaccine benefits in preventing COVID-19 mortality. Substantially increasing COVID-19 vaccinations will help Zambia reach targets and reduce COVID-19 mortality in the country. Acknowledgements: Lydia Chama (University Teaching Hospital, Lusaka); Martha Ilunga (Kawama Health Center, Kabwe); Florence Chanda Miti (Levy Mwanawasa University Teaching Hospital, Lusaka); Evelyn Mwamba (University Teaching Hospital, Lusaka); Naomi Charity Mwananyau (Levy Mwanawasa University Teaching Hospital, Lusaka); Francis D. Mwansa (Ministry of Health, Lusaka); Linda Musonda (University Teaching Hospital, Lusaka); Agness Mutaja (National Heart Hospital, Lusaka); Charles Mutemba (University Teaching Hospital, Lusaka); Prosperllina Ndhlovu (Ndola Teaching Hospital, Ndola); Amideos Nshikita (Maina Soko Medical Centre, Lusaka); Christabel Phiri (Levy Mwanawasa University Teaching Hospital, Lusaka); Constance Phiri (University Teaching Hospital, Lusaka); Miracle Phiri (Levy Mwanawasa University Teaching Hospital, Lusaka); Mary M. Siamupa (Livingstone Central Hospital, Livingstone); Vanessa Tayali (Kabwe Central Hospital, Kabwe); Harriet Nandi Zulu (Ndola Teaching Hospital, Ndola);

Attribution of Support: This work has been supported by the Zambia Ministry of Health and the U.S.

President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and

Prevention (CDC) and the CDC Emergency Response to the COVID-19 pandemic.

Authorship Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the funding agencies.

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

References 1. World Health Organization Regional Office for Africa (WHO AFRO). COVID-19 vaccination in the WHO African region; Monthly bulletin [Internet]. Brazzaville, Congo; Available from: https://apps.who.int/iris/bitstream/handle/10665/354270/CV-20220513-eng.pdf 2. Zambia National Public Health Institute. Zambia COVID-19 Statistics; Daily Status Update [Internet]. Available from: https://www.facebook.com/ZMPublicHealth/ 3. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. Lancet Glob Heal [Internet]. 2021;9(6):e773-81. Available from: http://dx.doi.org/10.1016/S2214-109X(21)00053-Χ Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-4. related mortality, 2020-21. Lancet (London, England). 2022 Apr;399(10334):1513-36. 5. Collie S, Champion J, Moultrie H, Bekker L-G, Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. Vol. 386, The New England journal of medicine. 2022. p. 494–6. 6. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022 Apr;386(16):1532-46. 7. Plumb ID, Feldstein LR, Barkley E, Posner AB, Bregman HS, Hagen MB, et al. Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr;71(15):549-55. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 8.

vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022 Jan;114:252-60.

311 9. Tenforde MW, Self WH, Gaglani M, Ginde AA, Douin DJ, Talbot HK, et al. Effectiveness of mRNA 312 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death -313 United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar;71(12):459-314 65. 315 10. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-316 19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021; 317 Bekker L-G, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al. Effectiveness of the 11. 318 Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a 319 single-arm, open-label, phase 3B, implementation study. Lancet (London, England). 2022 Mar;399(10330):1141-53. 320 321 Vaccines and Related Biological Products Advisory Committee Meeting February 26, 2021. In: 12. 322 FDA Briefing Document; Janssen Ad26COV2S Vaccine for the Prevention of COVID-19 [Internet]. 323 Available from: https://www.fda.gov/media/146217/download 324 13. Simwanza J, Hines JZ, Sinyange D, Sinyange N, Mulenga C, Hanyinza S, et al. COVID-19 vaccine 325 effectiveness during a prison outbreak when the Omicron was the dominant circulating variant— 326 Zambia, December 2021. medRxiv [Internet]. 2022; Available from: 327 https://www.medrxiv.org/content/10.1101/2022.05.06.22274701v1 328 Menezes NP, Simuzingili M, Debebe ZY, Pivodic F, Massiah E. What is driving COVID-19 vaccine 14. 329 hesitancy in Sub-Saharan Africa? [Internet]. World Bank Blogs. [cited 2022 Jun 27]. Available from: https://blogs.worldbank.org/africacan/what-driving-covid-19-vaccine-hesitancy-sub-330 331 saharan-africa 332 15. Africa Centres for Disease Control. COVID 19 Vaccine Perceptions: A 15 country study [Internet].

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

Addis Ababa, Ethiopia; Available from: https://africacdc.org/download/covid-19-vaccineperceptions-a-15-country-study/ 16. Lewis H, AI E. SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. medRxiv [Internet]. Available from: www.medrxiv.org/content/10.1101/2022.02.14.22270934v1 17. Salver SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet [Internet]. 2021;397(10281):1265–75. Available from: http://dx.doi.org/10.1016/S0140-6736(21)00632-2 18. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus Pandemic (COVID-19) [Internet]. Available from: https://ourworldindata.org/coronavirus Jassat W, Cohen C, Tempia S, Masha M, Goldstein S, Kufa T, et al. Risk factors for COVID-19-19. related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa🛭: a cohort study. Lancet HIV. 2021;3018(21):1–14. 20. Minchella P, Chanda D, Hines J, Fwoloshi S, Itoh M, Kampamba D, et al. The first four COVID-19 waves in Zambia: Comparison of epidemiologic and clinical characteristics among persons hospitalized for COVID-19. Pending Publ. 2022; 21. World Health Organization. COVID-19 Case Definition [Internet]. 2020. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance Case Definition-2020.2 22. Chanda D, Minchella PA, Kampamba D, Itoh M, Hines JZ, Fwoloshi S, et al. COVID-19 Severity and COVID-19—Associated Deaths Among Hospitalized Patients with HIV Infection — Zambia, March— December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(22):807–10. 23. GISAID - EpiCov [Internet]. [cited 2022 Feb 18]. Available from:

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

https://www.epicov.org/epi3/frontend#220b8c 24. World Health Organization (WHO). The WHO Global Clinical Platform for COVID-19 [Internet]. 2020. Available from: https://www.who.int/teams/health-care-readiness-clinical-unit/covid-19/data-platform. 25. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019 Jul;95:103208. 26. World Health Organization. COVID-19 Clinical Management; Living Guidance [Internet]. 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 27. Mwenda-Chimfwembe M, Saasa N, Bridges D. Genomic epidemiology of novel coronavirus -Africa Zambia-focused subsampling [Internet]. [cited 2022 Feb 16]. Available from: https://nextstrain.org/groups/SC2ZamPub/ncov/africa/zambia 28. UNAIDS. AIDSinfo | UNAIDS [Internet]. People living with HIV (all ages). Available from: http://aidsinfo.unaids.org/ 29. Thompson MG, Natarajan K, Irving SA. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19—Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021-. Morb Mortal Wkly Rep [Internet]. ePub: 21 J. Available from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm?s_cid=mm7104e3_x#suggestedcit ation 30. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S, Sunny S-K, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. N Engl J Med. 2022 Jan;

377	31.	Polinski JM, Weckstein AR, Batech M, Kabelac C, Kamath T, Harvey R, et al. Durability of the
378		Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations
379		in the US Before and During the Delta Variant Surge. JAMA Netw open. 2022 Mar;5(3):e222959.
380	32.	Lewis NM, Self WH, Gaglani M, Ginde AA, Douin DJ, Keipp Talbot H, et al. Effectiveness of the
381		Ad26.COV2.S (Johnson & Johnson) COVID-19 Vaccine for Preventing COVID-19 Hospitalizations
382		and Progression to High Disease Severity in the United States. Clin Infect Dis an Off Publ Infect
383		Dis Soc Am. 2022 Jun;
384	33.	Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical Characteristics
385		and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection
386		During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One
387		Hospital, California, July 15-September 23, 2021, and De. MMWR Morb Mortal Wkly Rep. 2022
388		Feb;71(6):217–23.
389	34.	Hui KPY, Ho JCW, Cheung M-C, Ng K-C, Ching RHH, Lai K-L, et al. SARS-CoV-2 Omicron variant
390		replication in human bronchus and lung ex vivo. Nature. 2022 Mar;603(7902):715–20.
391	35.	Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-CoV2373
392		Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20).
393	36.	Alcorn K. COVID-19 vaccines in people with HIV [Internet]. aidsmap. [cited 2022 Apr 26].
394		Available from: https://www.aidsmap.com/about-hiv/covid-19-vaccines-people-hiv
395	37.	Gushchin VA, Tsyganova E V, Ogarkova DA, Adgamov RR, Shcheblyakov D V, Glukhoedova N V, et
396		al. Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy.
397		EClinicalMedicine. 2022 Apr;46:101360.
398	38.	World Health Organization. Strategic Advisory Group of Experts (SAGE) on Immunization: Interim

statement on hybrid immunity and increasing population seroprevalence rates [Internet]. [cited 2022 Jun 27]. Available from: https://www.who.int/news/item/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates

Figure 1. Sample size flow diagram for analysis of COVID-19 vaccine effectiveness against in-hospital

mortality in Zambia, 2021-2022

403




Table 1. Characteristics and outcomes of patients admitted to COVID-19 treatment centers with known hospitalization outcome in Zambia, 2021-2022

Characteristic	Overall	Vaccinated	Unvaccinated	p-value*	
Characteristic	(N = 1,653)	(n = 236)	(n = 1,417)		
Age, median (IQR)	47 (30-65)	42 (29-61)	48 (30-66)	0.10	
(n miss = 3)					
Age group, n (%) (n miss = 3)					
0-17	78 (4.7)	4 (1.7)	74 (5.2)	0.02	
18-29	322 (19.5)	57 (24.3)	265 (18.7)		
30-44	370 (22.4)	60 (25.5)	310 (21.9)		
45-59	331 (20.1)	48 (20.4)	283 (20.0)		
≥60	549 (33.3)	66 (28.1)	483 (34.1)		
Sex, n (%)					
Female	852 (51.5)	133 (56.4)	719 (50.7)	0.13	
Male	801 (48.5)	103 (43.6)	698 (49.3)		
District, n (%) (n miss = 48)					
Lusaka	715 (44.5)	99 (42.3)	616 (44.9)	<0.01	
Ndola	426 (26.5)	36 (15.4)	390 (28.4)		
Kitwe	209 (13.0)	75 (32.1)	134 (9.8)		
Livingstone	139 (8.7)	15 (6.4)	124 (9.0)		
Kabwe	116 (7.2)	9 (3.8)	107 (7.8)		

Comorbidity number, n (%)*				
0	588 (35.6)	81 (34.3)	507 (35.8)	0.93
1	535 (32.3)	77 (32.6)	458 (32.3)	
2	326 (19.7)	46 (19.5)	280 (19.8)	
≥3	204 (12.3)	32 (13.6)	172 (12.1)	
Comorbidities, n (%) [†]				
Hypertension (n miss = 78)	564 (35.8)	79 (35.4)	485 (35.9)	0.96
HIV (n miss = 159)	266 (17.9)	35 (15.5)	231 (18.4)	0.35
Diabetes (n miss = 114)	222 (14.4)	41 (19.0)	181 (13.7)	0.05
Severe COVID-19 at admission, n	872 (53.1)	83 (35.3)	789 (56.1)	<0.01
(%) [‡] (n miss = 12)				
Mean length of stay, days (range)	2.5 (0-27)	1.9 (0-27)	2.6 (0-27)	<0.01
Hospitalized ≥5 days, n (%)	287 (17.4)	29 (12.3)	258 (18.2)	0.03
Died during hospitalization, n (%)	365 (22.1)	22 (9.3)	343 (24.2)	<0.01
Timing of 1 st vaccine dose, n (%)				
≥14 days before admission	-	85 (36.0)	-	-
0-13 days before admission	-	8 (3.4)	-	
After admission	-	0 (0.0)	-	-
Missing date	-	143 (60.6)	-	
Vaccination status, n (%) [¶]				
Fully	-	55 (23.3)	-	-

Partially	-	30 (12.7)	-	
Indeterminate	-	8 (3.4)	-	
Missing date	1	.43 (60.6)		
Median time since vaccination, days	52.5	(28-107)	-	_
(IQR) (n miss: 146)**				
Vaccine type, n (%) (n miss = 27)				
Ad26.COV2.S	- 1	.21 (57.9)	-	-
ChAdOx1-S	-	84 (40.2)	-	
BNT162b2	-	3 (1.4)	-	
mRNA-127	-	1 (0.5)	-	
Sinopharm BBIBP-CorV	-	0 (0.0)	-	

^{*} Chi-square test used for categorical variables and student t-test used for continuous variables

[†] Comorbidities included cardiac disease, hypertension, diabetes, other pulmonary disease, HIV, tuberculosis (active or previous), asthma, kidney disease, liver disease, neurological disorder, asplenia, malignant neoplasm, and current smoking. Only the most common comorbidity options are shown in the table. [‡] Severe COVID-19 was defined as an oxygen saturation <90% on room air, respiratory rate >30 breaths per minute, or receiving oxygen therapy

[¶] Full vaccination defined as receiving the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days prior to COVID-19 treatment center admission, partial vaccination defined as receiving the 1^{st} dose of a two-dose vaccine ≥14 days prior to admission but either not yet receiving the 2nd dose or receiving the 2nd dose ≤13 days prior to admission, and indeterminate vaccination status defined as receiving the 1^{st} COVID-19 vaccine dose ≤13 days prior to admission

** 146 missing date since first dose received. Three of these persons had date of second dose, meaning they could be classified as fully vaccinated in prior analyses

IQR: interquartile range

408

Table 2. COVID-19 vaccine effectiveness against progression to in-hospital mortality - Zambia, April 2021-March 2022

Vaccination status	Deaths in vaccinated	Deaths in vaccinated Vaccine effectiveness, 9		
Vaccination status	group*, n (%)			
		Crude VE	Adjusted VE [†]	
≥1 vaccine dose (n = 236)	22 (9.3)	67.8 (50.4-80.1)	64.8 (42.3-79.4)	
Vaccination status [‡]				
Full (n = 55)	6 (10.9)	61.7 (16.5-85.4)	60.9 (2.3-86.5)	
Partial (n = 30)	4 (13.3)	51.8 (-24.7-85.9)	61.3 (-15.8-89.7)	
Indeterminate (n = 8)	0 (0.0)	-	-	
Missing (n = 143)	12 (8.4)	71.3 (49.7-85.1)	63.4 (29.7-82.3)	
Time period (predominant variant) ^{¶,**}				
April to November 2021 (delta) (n = 46)	8 (17.4)	55.3 (7.5-80.9)	65.0 (22.5-85.8)	
December 2021 to March 2022 (omicron) (n = 190)	14 (7.4)	59.6 (30.2-78.3)	64.8 (31.4-82.9)	
Vaccine type [¶]				
ChAdOx1-S (n = 84)	9 (10.7)	62.1 (32.9-80.5)	65.2 (33.5-83.1)	

Ad26.COV2.S (n = 121)	10 (8.3)	69.9 (48.2-84.0)	61.1 (26.6-80.8)
	()	()	()

^{* 343 (24.2%)} patients died in the unvaccinated group (n = 1,417)

412

** In the delta variant predominant period, there were 706 unvaccinated patients, of whom 226 (32.0%) died during hospitalization. In the omicron variant predominant period, there were 711 unvaccinated patients, of whom 117 (16.5%) died during hospitalization.

Cl: confidence interval; VE: vaccine effectiveness

[†] Adjusted for age, sex, number of comorbid conditions, disease severity at admission (defined as oxygen saturation <90% on room air, respiratory rate >30 breaths per minute, or receiving oxygen therapy), hospitalization month, and COVID-19 treatment center

[‡] Full vaccination defined as receiving the 1st dose of a one-dose vaccine or 2nd dose of a two-dose vaccine ≥14 days prior to COVID-19 treatment center admission, partial vaccination defined as receiving the 1st dose of a two-dose vaccine ≥14 days prior to admission but either not yet receiving the 2nd dose or receiving the 2nd dose ≤13 days prior to admission, and indeterminate vaccination status defined as receiving the 1st COVID-19 vaccine dose ≤13 days prior to admission

[¶] Estimate for receipt of ≥1 COVID-19 vaccine dose

Table 3. In-hospital mortality by COVID-19 pandemic period (proxy for predominant variant) and vaccination status — Zambia, 2021-2022

	All patients, n (%)		Unvaccinated, n (%)			≥1 vaccine dose, n (%)			
Outcome	Delta	Omicron		Delta	Omicron		Delta	Omicron	
Outcome	period (n	period (n	p-value*	period (n	period (n	p-value*	period (n	period (n	p-value*
	= 752)	= 901)		= 706)	= 711)		= 46)	= 190)	
Severe illness at admission	552 (73.4)	320 (35.5)	<0.01	517 (73.2)	272 (38.3)	<0.01	35 (76.1)	48 (25.3)	<0.01
In-hospital mortality	234 (31.1)	131 (14.5)	<0.01	226 (32.0)	117 (16.5)	<0.01	8 (17.4)	14 (7.4)	0.05

Delta period defined as April to November 2021 and Omicron period defined as December 2021 through March 2022

413

414

^{*} Chi-square test or Fischer exact test where appropriate